Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update
PR Newswire•12/11/2026•16:30 ET
1
Key Highlights
- ➤Merger with North Immunology targets combined company operating under North Immunology name
- ➤$6.5 million cash and cash equivalents as of September 30, 2026
- ➤Operating expenses rose 77.2% to approximately $2.7 million
- ➤Phase 1 oncology study treated eight patients across three dosing cohorts
- ➤Workforce reductions implemented; legacy Hemopurifier activities may be wound down
Expert Statements
James Frakes, CEO and CFO of Aethlon Medical
“We advanced our clinical program during the quarter.”
James Frakes, CEO and CFO of Aethlon Medical
“We treated the second participant in the third and final dosing cohort of our Phase 1 oncology study in Australia.”
James Frakes, CEO and CFO of Aethlon Medical
“We have treated eight patients across the three dosing cohorts to date and continue to pursue enrollment of one additional patient.”
James Frakes, CEO and CFO of Aethlon Medical
“Given the anticipated timing of the proposed Merger with North Immunology, we have a limited window in which to complete enrollment.”
James Frakes, CEO and CFO of Aethlon Medical
“We intend to conclude patient recruitment in connection with the proposed Merger and subsequently compile the available clinical data for analysis.”
Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update PR Newswire
SAN DIEGO, Nov. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results for fiscal second quarter ended September 30, 2026, and provided a corporate update.
Get started
Create a free account to read the full story.